Lantern Pharma Soars 9.14% on FDA IND Clearance for Brain Cancer Therapy

Lantern Pharma's stock surged by 9.14% in pre-market trading on August 7, 2025, driven by significant developments in the company's pipeline and regulatory approvals.

Lantern Pharma has received clearance from the FDA for an Investigational New Drug (IND) application for a combination therapy targeting brain cancer. This approval marks a pivotal moment for the company, as it paves the way for clinical trials to commence, potentially leading to new treatment options for patients suffering from this aggressive form of cancer.

The IND clearance is a testament to Lantern Pharma's commitment to innovation and its ability to navigate the complex regulatory landscape. The company's focus on developing combination therapies that leverage multiple mechanisms of action is expected to enhance treatment efficacy and improve patient outcomes.

This regulatory milestone is likely to bolster investor confidence in Lantern Pharma's growth prospects, as the company continues to advance its pipeline of novel therapies. The successful initiation of clinical trials for the brain cancer combination therapy could attract further investment and partnerships, driving the company's long-term success.